LSTA

Lisata Therapeutics Inc

Add to Watchlist

Advanced Chart

2.690

+0.03(1.128%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.800

Open

2.650

VWAP

2.72

Vol

17.12K

Mkt Cap

23.13M

Low

2.605

Amount

46.54K

EV/EBITDA(TTM)

Total Shares

8.31M

-2.96M

EV/OCF(TTM)

P/S(TTM)

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.755

+37.27%

-0.665

+12.71%

-0.650

+6.56%

Estimates Revision

The market is revising No Change the revenue expectations for Lisata Therapeutics, Inc. (LSTA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 6.32%.

EPS Estimates for FY2025

Revise Upward

+4.49%

In Past 3 Month

Stock Price

Go Up

+6.32%

In Past 3 Month

1 Analyst Rating

457.62% Upside

Wall Street analysts forecast LSTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LSTA is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

457.62% Upside

Current: 2.690

Low

15.00

Averages

15.00

High

15.00

457.62% Upside

Current: 2.690

Low

15.00

Averages

15.00

High

15.00

Brookline

Buy

maintain

$20 -> $32

2025-07-15

Reason

Brookline

Price Target

$20 -> $32

2025-07-15

maintain

Buy

Reason

Brookline raised the firm's price target on Lisata Therapeutics to $32 from $20 and keeps a Buy rating on the shares. The firm cites extended patent protection for the target increase after Lisata received a new patent for certepetide through March 2040.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$15

2024-12-11

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$15

2024-12-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$15

2024-11-21

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$15

2024-11-21

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$15

2024-09-18

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$15

2024-09-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$15

2024-08-13

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$15

2024-08-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lisata Therapeutics Inc (LSTA.O) is -1.17, compared to its 5-year average forward P/E of -1.61. For a more detailed relative valuation and DCF analysis to assess Lisata Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.61

Current PE

-1.17

Overvalued PE

-0.75

Undervalued PE

-2.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.76

Current EV/EBITDA

0.12

Overvalued EV/EBITDA

1.80

Undervalued EV/EBITDA

-0.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.61

Current PS

0.00

Overvalued PS

12.27

Undervalued PS

-5.06